Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (VNRX) is pioneering epigenetic diagnostics through its nucleosomics platform, developing non-invasive blood tests for early cancer detection and NETosis-related conditions. This resource provides investors and healthcare professionals with comprehensive access to verified company developments and clinical milestones.
Our curated news collection delivers timely updates on regulatory progress, partnership announcements, and research breakthroughs. Users will find essential information spanning clinical trial results, licensing agreements, veterinary diagnostic expansions, and financial performance reports.
The page features critical updates including technology validations, international market entries, and peer-reviewed study publications. All content is rigorously verified to ensure accuracy and relevance for strategic decision-making.
Bookmark this page for structured access to VolitionRx's evolving diagnostic solutions across human and animal health sectors. Check regularly for authoritative reporting on innovations transforming routine disease detection through advanced epigenetic analysis.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced its third quarter 2020 results, highlighting significant advancements in its product launch and clinical programs. The Nu.Q™ Vet Cancer Screening Test is set to launch on November 30, 2020. The company is working with Diagnostic Oncology CRO LLC on a clinical trial for Non-Hodgkin's Lymphoma, expecting FDA submissions 10-12 months into the trial. Financially, cash equivalents rose to approximately $21 million, and a burn rate of $1.6-1.7 million per month is noted. The company anticipates substantial revenue potential from its veterinary diagnostics.
VolitionRx Limited (NYSE AMERICAN: VNRX) has released a report titled A Look to the Future of Cancer Diagnostics, featuring insights from leading veterinary oncology experts. This report highlights the significance of early cancer detection and the introduction of the Nu.Q™ Vet Cancer Screening Test. The test aims to streamline the diagnostic process for canine cancers, including lymphoma and hemangiosarcoma, using a simple blood sample. The report emphasizes the potential benefits of early detection for improving treatment outcomes in pets.
VolitionRx Limited (NYSE AMERICAN: VNRX) will host a conference call on November 13, 2020, at 8:30 a.m. Eastern time to discuss its third quarter 2020 financial and operational results and provide a business update. The call will be led by CEO Cameron Reynolds and CFO David Vanston, covering recent developments, clinical trials, and milestones. A live audio webcast will be available on the investor relations page of Volition's website. The call can also be replayed until November 27, 2020.
On October 21, 2020, VolitionRx Limited (NYSE AMERICAN: VNRX) announced the release of a video from its recent capital markets day event. This event highlighted the upcoming launch of the Nu.Q™ Vet Cancer Screening Test, set for this year, alongside updates on recent developments and clinical trials focused on blood cancer. The presentation featured key insights from executives, including product launch data and clinical trial updates. The video and additional materials are available on Volition's website.
VolitionRx Limited (NYSE AMERICAN: VNRX) is hosting a capital markets day on Oct. 20, 2020, at 8:00 AM ET, featuring a live stream outlining the launch of their Nu.Q™ Vet Cancer Screening Test. Presentations will cover new data and the roll-out plan for this diagnostic tool, expected to launch this year. Key executives will present insights into ongoing clinical trials and product development. The event will be recorded and accessible on Volition's website starting Oct. 21. Volition aims to provide cost-effective blood tests for cancer diagnosis in humans and animals.
VolitionRx Limited (NYSE AMERICAN: VNRX) announces positive data on the Nu.Q™ Vet Cancer Screening Test for Lymphoma and Hemangiosarcoma. The test, expected to launch soon, shows high sensitivity (AUC 87.3%) and specificity (AUC 97.6%) in detecting these cancers in dogs. Cancer is the leading cause of death among dogs over two years in the U.S., with Lymphoma and Hemangiosarcoma accounting for one-third of cases. The objective is to enhance early diagnosis, thereby improving treatment outcomes and quality of life for dogs.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced details for its Capital Markets Day on October 20, 2020, at 8:00 a.m. ET. The event will focus on the launch and commercial rollout of the Nu.Q™ Vet Cancer Screening Test and provide updates on ongoing clinical trials. Presentations will be made by key executives including Cameron Reynolds, Dr. Heather Wilson-Robles, and Dr. Jason Terrell. Registration for the live event is available here. A recording will be available on Volition's website on October 21.
VolitionRx Limited (NYSE AMERICAN: VNRX) will showcase two abstracts for its Nu.Q™ Vet Cancer Screening Test at the 2020 Veterinary Cancer Society (VCS) Virtual Annual Conference from October 15-17. The first abstract on dogs with lymphoma will be presented on October 16 at 1:30 p.m. ET, while the second on dogs with hemangiosarcoma will be on October 17 at 11:15 a.m. ET. Volition will release more details on October 16, and the abstracts will be available on their website starting October 19.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced a capital markets day on October 20, 2020, starting at 8:15 a.m. ET. The event will be hosted by Cameron Reynolds, CEO, and feature Dr. Heather Wilson-Robles, presenting data on the Nu.Q™ Vet Cancer Screening Test. Attendees will receive updates on Volition's clinical trials and developments. Volition specializes in epigenetics, focusing on blood tests for early cancer diagnosis, with operations in Belgium, Texas, London, and Singapore.
VolitionRx Limited (NYSE AMERICAN: VNRX) will present at five virtual conferences in September 2020. CEO Cameron Reynolds and EVP Scott Powell will share insights on the company’s milestones and financial results. Key conferences include LD Micro 500 on September 1, GCFF on September 10, Cantor Healthcare on September 15, Life Sciences Forum on September 17, and Oppenheimer Summit on September 21. The company focuses on developing cost-effective blood tests for early cancer diagnosis, utilizing its Nucleosomics™ technology.
FAQ
What is the current stock price of Volitionrx (VNRX)?
What is the market cap of Volitionrx (VNRX)?
